These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1022 related articles for article (PubMed ID: 22382007)

  • 21. Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas.
    Zhong S; Yeo W; Tang MW; Wong N; Lai PB; Johnson PJ
    Clin Cancer Res; 2003 Aug; 9(9):3376-82. PubMed ID: 12960125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methylation of RAS association domain family protein 1A as a biomarker of lung cancer.
    Grote HJ; Schmiemann V; Geddert H; Bocking A; Kappes R; Gabbert HE; Sarbia M
    Cancer; 2006 Apr; 108(2):129-34. PubMed ID: 16444703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
    Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
    Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
    Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma.
    Friedrich MG; Chandrasoma S; Siegmund KD; Weisenberger DJ; Cheng JC; Toma MI; Huland H; Jones PA; Liang G
    Eur J Cancer; 2005 Nov; 41(17):2769-78. PubMed ID: 16242928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hypermethylation of promoter region of RAS association domain family gene1A in esophageal squamous cell carcinoma and significance thereof].
    Cong DG; Wang SF
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2932-4. PubMed ID: 18261310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RUNX3 methylation in normal surrounding urothelium of patients with non-muscle-invasive bladder cancer: potential role in the prediction of tumor progression.
    Jeong P; Min BD; Ha YS; Song PH; Kim IY; Ryu KH; Kim JH; Yun SJ; Kim WJ
    Eur J Surg Oncol; 2012 Nov; 38(11):1095-100. PubMed ID: 22884471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer.
    Kim DH; Kim JS; Ji YI; Shim YM; Kim H; Han J; Park J
    Cancer Res; 2003 Jul; 63(13):3743-6. PubMed ID: 12839968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor.
    Kim EJ; Kim YJ; Jeong P; Ha YS; Bae SC; Kim WJ
    J Urol; 2008 Sep; 180(3):1141-5. PubMed ID: 18639281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression.
    Yim MS; Ha YS; Kim IY; Yun SJ; Choi YH; Kim WJ
    J Urol; 2011 Feb; 185(2):701-5. PubMed ID: 21168882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer.
    Fahmy M; Mansure JJ; Brimo F; Yafi FA; Segal R; Althunayan A; Hicks J; Meeker A; Netto G; Kassouf W
    Hum Pathol; 2013 Sep; 44(9):1766-72. PubMed ID: 23623586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma.
    Dhawan D; Hamdy FC; Rehman I; Patterson J; Cross SS; Feeley KM; Stephenson Y; Meuth M; Catto JW
    J Pathol; 2006 Jul; 209(3):336-43. PubMed ID: 16639696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of Bcl-2 and Bax tumor cell expression in patients with non muscle-invasive bladder cancer receiving bacillus Calmette-Guerin immunotherapy.
    Ajili F; Kaabi B; Darouiche A; Tounsi H; Kourda N; Chebil M; Manai M; Boubaker S
    Ultrastruct Pathol; 2012 Feb; 36(1):31-9. PubMed ID: 22292735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients.
    Balgkouranidou I; Matthaios D; Karayiannakis A; Bolanaki H; Michailidis P; Xenidis N; Amarantidis K; Chelis L; Trypsianis G; Chatzaki E; Lianidou ES; Kakolyris S
    Mutat Res; 2015 Aug; 778():46-51. PubMed ID: 26073472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of bladder neck involvement on progression in patients with primary non-muscle invasive bladder cancer: a prospective validation study.
    Kobayashi S; Fujii Y; Koga F; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Masuda H; Kihara K
    Urol Oncol; 2014 Jan; 32(1):38.e29-36. PubMed ID: 23702087
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer.
    Wang Y; Yu Z; Wang T; Zhang J; Hong L; Chen L
    Lung Cancer; 2007 May; 56(2):289-94. PubMed ID: 17267069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
    Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
    Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
    Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
    Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 52.